Clinical trials: Neoadjuvant Systemic Therapy
Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC)
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
This is a multicenter, non-interventional, prospective and retrospective observational patient registry study of adults with muscle-invasive bladder cancer receiving perioperative systemic therapy as part of routine clinical…
- Trial name
- GUARDIANS (NCT07855926)
- Testing
- Perioperative Systemic Therapy Registry
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- LMU Klinikum
Breast Carcinoma
Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma
MicroRNAs (miRNAs) are involved in the development and progression of malignant tumors. In breast cancer, differential miRNA expression has been demonstrated across breast cancer subtypes, with both tumor-promoting and tumor…
- Trial name
- NCT05151224
- Testing
- microRNA 21
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Breast Cancer, Triple Negative Breast Cancer
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
This study evaluates whether SLNB can safely be omitted in breast cancer patients with HER2+ or TN tumors who achieve a radiological complete response on MRI after neoadjuvant systemic therapy
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Sentinel Lymph Node
- Trial name
- ASICS (NCT04225858)
- Testing
- Omission of sentinel lymph node biopsy
- Volunteers
- 340 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
Background Clinical N3 (cN3) breast cancer represents a high-risk subgroup of locally advanced disease. After neoadjuvant systemic therapy (NST), patients who achieve a clinical complete response (cCR) in initially involved but…
- Trial name
- NCT07829848
- Testing
- standard boost, boost omission
- Where
- China
- Volunteers
- 534 people
- Sponsor
- Fudan University
Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Main Purpose of this study is to determine the efficacy and safety of Cadonilimab combined with chemotherapy (cisplatin) for locally advanced cervical cancer.
- Conditions
- Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion
- Trial name
- NCT07104149
- Testing
- Cadonilimab combined with cisplatin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Breast Cancer
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with…
- Trial name
- NCT05629585
- Testing
- Dato-DXd, Durvalumab, Capecitabine
- Where
- 276 sites in United States, Belgium and 15 more
- Volunteers
- 1,174 people
- Sponsor
- AstraZeneca
Breast Neoplasms
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
- Trial name
- NCT00353483
- Testing
- Peripheral blood draw, Breast tissue collection, Bone marrow biopsy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Immunotherapy Gastrict Cancer, Inflammation Biomarkers
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.
- Conditions
- Immunotherapy Gastrict Cancer, Inflammation Biomarkers, Gastric Cancers
- Trial name
- NCT06706466
- Testing
- observational study
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Chang-Ming Huang, Prof.
Breast Cancer, Chemotherapy Effect
Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment
The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the…
- Conditions
- Breast Cancer, Chemotherapy Effect, Sentinel Lymph Node
- Trial name
- MagNeo (NCT05985551)
- Testing
- SLND or TAD by the magnetic technique (SPIO)
- Where
- Sweden
- Volunteers
- 114 people
- Sponsor
- Uppsala University
Gastric Cancer, Neoadjuvant Chemotherapy
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer.
- Conditions
- Gastric Cancer, Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, Systemic Inflammatory Response Syndrome (SIRS)
- Trial name
- NCT03493880
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Nasopharyngeal Carcinoma
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Hypothesis We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab prior to systemic cisplatin and gemcitabine chemotherapy to transiently "normalise" tumour vasculature in patients with…
- Trial name
- NCT01309633
- Testing
- 12.5mg sunitinib with Cisplatin and Gemcitabine, 25mg Sunitinib alternating with Cisplatin and Gemcitabine, 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
High Grade Upper Tract Urothelial Carcinoma
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer.
- Trial name
- NCT02412670
- Testing
- Methotrexate, Vinblastine, Doxorubicin
- Where
- 134 sites in United States
- Volunteers
- 36 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cutaneous Squamous Cell Carcinoma (CSCC)
Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.
In the context where advanced cutaneous squamous cell carcinoma (cSCC) is currently a public health issue due to its increasing incidence and where its management is rapidly evolving, it is essential to characterize and monitor…
- Trial name
- CAREPI (NCT07606508)
- Testing
- Systemic treatment
- Where
- 29 sites in France
- Volunteers
- 1,500 people
- Sponsor
- University Hospital, Lille
Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma
OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma
Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy…
- Conditions
- Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OPPOSITE (NCT03429816)
- Testing
- Biopsy
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital Heidelberg
Breast Cancer, Residual
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (>50%) risk of future life-threatening recurrences and death.
- Trial name
- NCT04703244
- Testing
- chemotherapy or endocrine therapy for breast cancer
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Mayo Clinic
Stage III Prostate Cancer, Stage IIIA Prostate Cancer
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
This phase I trial studies the side effects of anti-PD-1 monoclonal antibody REGN2810 (REGN2810) and/or ipilimumab when given together with stereotactic body radiation therapy before surgery in treating participants with prostate…
- Conditions
- Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer
- Trial name
- NCT03477864
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk…
- Trial name
- NCT04928261
- Testing
- Trastuzumab
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer, Chemotherapy Effect
Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer
To evaluate of the value of radical prostatectomy and extended pelvic lymph node dissection in locally advanced prostate cancer after neoadjuvant hormonal therapy with or without docetaxel chemotherapy.
- Conditions
- Prostate Cancer, Chemotherapy Effect, Hormone Sensitive Prostate Cancer, Locally Advanced Prostate Carcinoma
- Trial name
- NCT04220398
- Testing
- Neoadjuvant chemotherapy combined with hormone therapy, Neoadjuvant hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
- Volunteers
- 475 people
- Sponsor
- RenJi Hospital
Thyroid Neoplasms
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI ± TKI) can render locally…
- Trial name
- NCT07010393
- Testing
- Dabrafenib, Trametinib, Selpercatinib
- Where
- China
- Volunteers
- 335 people
- Sponsor
- Fujian Medical University
Intraocular Retinoblastoma
Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
This phase III trial is studying how well giving carboplatin and vincristine together with standard local ophthalmic therapy works in treating children with intraocular retinoblastoma.
- Trial name
- NCT00079417
- Testing
- Carboplatin, Cryosurgery, Infrared Laser Therapy
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group